



Selective IgA Deficiency (sIgAD) is a common primary immunodeficiency. It has a prevalence of approximately 1 in 600 in the UK.

The majority of people with slgAD are asymptomatic and the condition is often picked up incidentally on testing based around IgA autoantibodies (e.g. coeliac screen).

Patients usually fall into one of three categories:

- **Asymptomatic** (majority). No specific treatment is required.
- Increased incidence of allergic and autoimmune disease. No deviation from standard management of these conditions is required.
- **Recurrent infections**. In this case, slgAD may be associated with another immune defect and requires investigation in an immunology clinic.

Further information and a patient information leaflet on selective IgA deficiency can be found at:

immunodeficiencyuk.org

in the section on resources for patients, carers and professionals.

The majority of patients with sIgAD do not require specialist input. Referrals should be considered for patients with recurrent, severe, unusual or persistent infections.